Literature DB >> 18031728

Hypotensive effect of UDP on intraocular pressure in rabbits.

Anna Markovskaya1, Almudena Crooke, Ana I Guzmán-Aranguez, Assumpta Peral, Airat U Ziganshin, Jesús Pintor.   

Abstract

Nucleotides can modify intraocular pressure (IOP). We have tested the ability of uridine-5'-diphosphate, UDP, for modulating IOP in New Zealand white rabbits. Uridine 5' diphosphate, UDP, reduced IOP by 82.9+/-2.6% compared to control. Dose-response analysis demonstrated a concentration dependent pattern which presented a pD(2) value of 7.57+/-1.45, equivalent to an EC(50) of 26.91 nM. Of all the tested P2 receptor antagonists, suramin, pyridoxalphosphate-6-azophenyl-2, 4-disulfonic acid (PPADS) and Reactive Blue 2 (RB-2), only the last two were able to reverse the action triggered by UDP. Altogether, UDP acting probably on P2Y(6) receptors present on the ciliary processes, can reduce intraocular pressure, indicating that this substance may be used for the treatment of ocular hypertension and glaucoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18031728     DOI: 10.1016/j.ejphar.2007.10.040

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.

Authors:  Hiroshi Maruoka; Matthew O Barrett; Hyojin Ko; Dilip K Tosh; Artem Melman; Lauren E Burianek; Ramachandran Balasubramanian; Barkin Berk; Stefano Costanzi; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-06-10       Impact factor: 7.446

2.  2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.

Authors:  Shay Eliahu; Alba Martín-Gil; María Jesús Perez de Lara; Jesús Pintor; Jean Camden; Gary A Weisman; Joanna Lecka; Jean Sévigny; Bilha Fischer
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 3.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits.

Authors:  Alba Martin-Gil; María Jesús Perez de Lara; Almudena Crooke; Concepción Santano; Assumpta Peral; Jesus Pintor
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y6 Receptor Agonists.

Authors:  Kiran S Toti; Shanu Jain; Antonella Ciancetta; Ramachandran Balasubramanian; Saibal Chakraborty; Ryan Surujdin; Zhen-Dan Shi; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2017-09-06       Impact factor: 3.597

Review 6.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

7.  Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma.

Authors:  Begoña Fonseca; Alejandro Martínez-Águila; María J Pérez de Lara; Jesús Pintor
Journal:  Purinergic Signal       Date:  2016-11-16       Impact factor: 3.765

8.  Effect of CO(2) laser sclerectomy with iridectomy on ocular hypertension in rabbits.

Authors:  Zhi-Xiao Xue; Ying-Xin Li; Yan-Shan Xu; Jiu-Min Yang
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

9.  Thymidine 5'-O-monophosphorothioate induces HeLa cell migration by activation of the P2Y6 receptor.

Authors:  Edyta Gendaszewska-Darmach; Marcin Szustak
Journal:  Purinergic Signal       Date:  2016-01-08       Impact factor: 3.765

10.  A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist.

Authors:  Tali Fishman Jacob; Vijay Singh; Mudit Dixit; Tamar Ginsburg-Shmuel; Begoña Fonseca; Jesus Pintor; Moussa B H Youdim; Dan T Major; Orly Weinreb; Bilha Fischer
Journal:  Purinergic Signal       Date:  2018-07-17       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.